Galapagos NVGLPG announced positive top line data from a phase I randomized, double blind, placebo controlled study on GLPG1837 for the treatment of patients with class III mutation in cystic fibrosis. Data revealed that the candidate was safe and
Forex – financial instrument.Forex news
Galapagos NVGLPG announced positive top line data from a phase I randomized, double blind, placebo controlled study on GLPG1837 for the treatment of patients with class III mutation in cystic fibrosis. Data revealed that the candidate was safe and